<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39247108</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1394-195X</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Malaysian journal of medical sciences : MJMS</Title><ISOAbbreviation>Malays J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis.</ArticleTitle><Pagination><StartPage>14</StartPage><EndPage>34</EndPage><MedlinePgn>14-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21315/mjms2024.31.4.2</ELocationID><Abstract><AbstractText>Atherosclerosis is characterised by the accumulation of fatty deposits and plaque as a result of a continuously high level of low-density lipoprotein cholesterol (LDL-C) in the blood. The primary objective of this research is to assess the current status of knowledge, research endeavours and developmental trajectories about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in correlation with atherosclerosis treatment. Additionally, this study aims to compile bibliometric and scientometric investigations within this domain through rigorous scientometric analysis. Analysing the bibliometric landscape and global research trends associated with PCSK9 inhibitors can contribute valuable insights into comprehending atherosclerosis. This is exemplified by examining publications within the Web of Science Core Collection (WOSCC) database from 2008 to 2022. Citespace was used for frequency, co-occurrence, co-citation, grouping and burst analysis, and Microsoft Excel was used to manage descriptive datasets. Eight hundred eighty-five publications available from WOSCC database between the years 2008 and 2022 were extracted and examined. Over the period, 3,138 collaborating institutions from 87 countries, a staggering 7,750 writers involved and 325 distinct journals published about PCSK9 inhibitors studies. Among authors, Sabatine et al. and the journal <i>The New England Journal of Medicine</i> has had the most significant impact. Lipid-lowering therapy and bempedoic acid are the most prominent topical clusters associated with PCSK9 inhibitors, and the most often used keywords are efficacy, safety and PCSK9 inhibitors. We believe this is the first comprehensive analysis of PCSK9 inhibitors research and publications conducted using Scientometric. These results demonstrate the nascence of PCSK9 inhibitors research. They may encourage a wide range of stakeholders, particularly early career researchers from various disciplines, to work together in the future.</AbstractText><CopyrightInformation>© Penerbit Universiti Sains Malaysia, 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matin</LastName><ForeName>Abdul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Food Processing and Engineering, Faculty of Food Science and Technology, Chattogram Veterinary and Animal Sciences University, Chattogram, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaudhry</LastName><ForeName>Gul-E-Saba</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azra</LastName><ForeName>Mohamad Nor</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazali</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Marine Science, Faculty of Fisheries and Marine Science, University of Teuku Umar, West Aceh, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeong</LastName><ForeName>Yik Sung</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tengku Muhammad</LastName><ForeName>Tengku Sifzizul</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Institute of Climate Adaptation and Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Malaysia</Country><MedlineTA>Malays J Med Sci</MedlineTA><NlmUniqueID>101126308</NlmUniqueID><ISSNLinking>1394-195X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PCSK9</Keyword><Keyword MajorTopicYN="N">PCSK9 inhibitors</Keyword><Keyword MajorTopicYN="N">atherosclerosis</Keyword><Keyword MajorTopicYN="N">bempedoic acid</Keyword><Keyword MajorTopicYN="N">lipid-lowering therapy</Keyword></KeywordList><CoiStatement>Conflict of Interest: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>9</Day><Hour>5</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39247108</ArticleId><ArticleId IdType="pmc">PMC11377008</ArticleId><ArticleId IdType="doi">10.21315/mjms2024.31.4.2</ArticleId><ArticleId IdType="pii">02mjms3104_ra</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Violi F, Nocella C, Loffredo L, Carnevale R, Pignatelli P. Interventional study with vitamin E in cardiovascular disease and meta-analysis. Free Radic Biol Med. 2022;178(November 2021):26–41. doi: 10.1016/j.freeradbiomed.2021.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2021.11.027</ArticleId><ArticleId IdType="pubmed">34838937</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019;20(4):1–28. doi: 10.3390/ijms20040904.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20040904</ArticleId><ArticleId IdType="pmc">PMC6413130</ArticleId><ArticleId IdType="pubmed">30791450</ArticleId></ArticleIdList></Reference><Reference><Citation>Amput P, McSweeney C, Palee S, Phrommintikul A, Chattipakorn SC, Chattipakorn N. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Biomed Pharmacother. 2019;109(October 2018):1171–1180. doi: 10.1016/j.biopha.2018.10.138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2018.10.138</ArticleId><ArticleId IdType="pubmed">30551367</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyanarayana, Chakrapani . Biochemistry. 4th ed. A division of Reed Elsevier India Private Limited: Elsevier; 2013.</Citation></Reference><Reference><Citation>Mohamad H, Razak MFA, Kamaruddin NN, Din LHM, Asari A, Andriani Y, et al. PCSK9 inhibitory activity of marine-derived compounds, aaptaminoids, and benzamide originated from Aaptos aaptos and Acanthaster planci as a potential treatment for atherosclerosis. J Appl Pharm Sci. 2020;10(8):111–123. doi: 10.7324/JAPS.2020.10813.</Citation><ArticleIdList><ArticleId IdType="doi">10.7324/JAPS.2020.10813</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Xu C. Natural phenolic compounds as anti-obesity and anti-cardiovascular disease agent. Diet Phytochem. 2021:205–221. doi: 10.1007/978-3-030-72999-8_11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-72999-8_11</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang B, Cai X-Y, Gu N. marine natural products and coronary artery disease. Front Cardiovasc Med. 2021;8(September):1–12. doi: 10.3389/fcvm.2021.739932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.739932</ArticleId><ArticleId IdType="pmc">PMC8490644</ArticleId><ArticleId IdType="pubmed">34621803</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JH, Ae Bang M, Jang CH, Jo H, Jung SK, Ki SH. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression. J Nutr Biochem. 2015;26:1393–1400. doi: 10.1016/j.jnutbio.2015.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jnutbio.2015.07.009</ArticleId><ArticleId IdType="pubmed">26320675</ArticleId></ArticleIdList></Reference><Reference><Citation>KPAD, Martin A. Recent insights into the molecular regulators and mechanisms of taurine to modulate lipid metabolism: a review. Crit Rev Food Sci Nutr. 2022;63:6005–6017. doi: 10.1080/10408398.2022.2026873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2022.2026873</ArticleId><ArticleId IdType="pubmed">35040723</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack A, Mohd MA, Kamaruddin NN, Mohd Din LH, Hajri NA, Tengku Muhammad TS. Acaudina molpadioides mediates lipid uptake by suppressing PCSK9 transcription and increasing LDL receptor in human liver cells. Saudi J Biol Sci. 2021;28(12):7105–7116. doi: 10.1016/j.sjbs.2021.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sjbs.2021.08.003</ArticleId><ArticleId IdType="pmc">PMC8626262</ArticleId><ArticleId IdType="pubmed">34867013</ArticleId></ArticleIdList></Reference><Reference><Citation>Adorni MP, Zimetti F, Lupo MG, Ruscica M, Ferri N. Naturally occurring PCSK9 inhibitors. Nutrients. 2020;12(5) doi: 10.3390/NU12051440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/NU12051440</ArticleId><ArticleId IdType="pmc">PMC7284437</ArticleId><ArticleId IdType="pubmed">32429343</ArticleId></ArticleIdList></Reference><Reference><Citation>Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13(6):544–552. doi: 10.1007/s11886-011-0220-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-011-0220-3</ArticleId><ArticleId IdType="pmc">PMC3234107</ArticleId><ArticleId IdType="pubmed">21968696</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Bélanger JS, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100(3):928–933. doi: 10.1073/pnas.0335507100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0335507100</ArticleId><ArticleId IdType="pmc">PMC298703</ArticleId><ArticleId IdType="pubmed">12552133</ArticleId></ArticleIdList></Reference><Reference><Citation>Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156. doi: 10.1038/ng1161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1161</ArticleId><ArticleId IdType="pubmed">12730697</ArticleId></ArticleIdList></Reference><Reference><Citation>Farnier M. PCSK9: From discovery to therapeutic applications. Arch Cardiovasc Dis. 2014;107(1):58–66. doi: 10.1016/j.acvd.2013.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acvd.2013.10.007</ArticleId><ArticleId IdType="pubmed">24373748</ArticleId></ArticleIdList></Reference><Reference><Citation>Waiz M, Alvi SS, Khan MS, Product N, Product N. Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management. EXCLI J. 2022;21:47–76. doi: 10.17179/excli2021-4453.</Citation><ArticleIdList><ArticleId IdType="doi">10.17179/excli2021-4453</ArticleId><ArticleId IdType="pmc">PMC8859648</ArticleId><ArticleId IdType="pubmed">35221836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L, Liu R, Zhou Z, Xu X, Feng S, Kushmaro A, et al. Probiotic characteristics of Lactiplantibacillus plantarum N-1 and its cholesterol-lowering effect in hypercholesterolemic rats. Probiotics Antimicrob Proteins. 2022. (0123456789)</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-021-09886-1</ArticleId><ArticleId IdType="pubmed">35064922</ArticleId></ArticleIdList></Reference><Reference><Citation>Azra MN, Mohd Noor MI, Zekker I. A scientometric analysis of international publication trends in oyster research. Front Mar Sci. 2022;9(October) doi: 10.3389/fmars.2022.998542.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmars.2022.998542</ArticleId></ArticleIdList></Reference><Reference><Citation>Azra MN, Mohd Noor MI, Sung YY, Dawood MAO, Ghaffar MA. Trends and developments in thermal tolerance: a scientometric research study. J Therm Biol. 2022;106(March):103234. doi: 10.1016/j.jtherbio.2022.103234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtherbio.2022.103234</ArticleId><ArticleId IdType="pubmed">35636885</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni SS, Edwards DJ. A bibliometric review on the implications of renewable offshore marine energy development on marine species. Aquac Fish. 2022;7(2):211–222. doi: 10.1016/j.aaf.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aaf.2021.10.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Aryadoust V, Ang BH. Exploring the frontiers of eye tracking research in language studies: a novel co-citation scientometric review. Comput Assist Lang Learn. 2021;34(7):898–933. doi: 10.1080/09588221.2019.1647251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09588221.2019.1647251</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Leydesdorff L. Patterns of connections and movements in dual-map overlays: a new method of publication portfolio analysis. J Am Soc Inf Sci Technol. 2013;64(July):1852–1863. doi: 10.1002/asi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/asi</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A. 2004;101(Suppl 1):5303–5310. doi: 10.1073/pnas.0307513100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307513100</ArticleId><ArticleId IdType="pmc">PMC387312</ArticleId><ArticleId IdType="pubmed">14724295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Chen Y, Horowitz M, Hou H, Liu Z, Pellegrino D. Towards an explanatory and computational theory of scientific discovery. J Informetr. 2009;3(3):191–209. doi: 10.1016/j.joi.2009.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joi.2009.03.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS ONE. 2019;14(10) doi: 10.1371/journal.pone.0223994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0223994</ArticleId><ArticleId IdType="pmc">PMC6822756</ArticleId><ArticleId IdType="pubmed">31671124</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y, Yin J, Wu B. Climate change and tourism: a scientometric analysis using CiteSpace. J Sustain Tour. 2018;26(1):108–126. doi: 10.1080/09669582.2017.1329310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09669582.2017.1329310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500–1509. doi: 10.1056/nejmoa1500858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1500858</ArticleId><ArticleId IdType="pubmed">25773607</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/nejmoa1615664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1615664</ArticleId><ArticleId IdType="pubmed">28304224</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499. doi: 10.1056/nejmoa1501031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1501031</ArticleId><ArticleId IdType="pubmed">25773378</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/nejmoa1801174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1801174</ArticleId><ArticleId IdType="pubmed">30403574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon CP, Kumar A. Treatment of overweight and obesity: Lifestyle, pharmacologic, and surgical options. Clin Cornerstone. 2009;9(4):55–71. doi: 10.1016/S1098-3597(09)80005-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1098-3597(09)80005-7</ArticleId><ArticleId IdType="pubmed">19789064</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192. doi: 10.1016/S0140-6736(11)60739-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60739-3</ArticleId><ArticleId IdType="pmc">PMC3145073</ArticleId><ArticleId IdType="pubmed">21663949</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy SM, Neeland IJ, Turer AT, Vega GL. Waist circumference as measure of abdominal fat compartments. J Obes. 2013;2013(1) doi: 10.1155/2013/454285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/454285</ArticleId><ArticleId IdType="pmc">PMC3665262</ArticleId><ArticleId IdType="pubmed">23762536</ArticleId></ArticleIdList></Reference><Reference><Citation>Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc. 2013;2(2):1–7. doi: 10.1161/JAHA.112.000028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.112.000028</ArticleId><ArticleId IdType="pmc">PMC3647281</ArticleId><ArticleId IdType="pubmed">23537802</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–571. doi: 10.1016/S0140-6736(12)61190-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61190-8</ArticleId><ArticleId IdType="pmc">PMC3774022</ArticleId><ArticleId IdType="pubmed">22883507</ArticleId></ArticleIdList></Reference><Reference><Citation>Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi: 10.1056/nejmoa1310907.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejmoa1310907</ArticleId><ArticleId IdType="pubmed">24251359</ArticleId></ArticleIdList></Reference><Reference><Citation>Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi: 10.1093/eurheartj/ehz455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehz455</ArticleId><ArticleId IdType="pubmed">31504418</ArticleId></ArticleIdList></Reference><Reference><Citation>Adriaanse LS, Rensleigh C. Web of science, scopus and google scholar a content comprehensiveness comparison. Electron Libr. 2013;31(6):727–744. doi: 10.1108/EL-12-2011-0174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1108/EL-12-2011-0174</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Ilan J. Which H-index? - A comparison of WoS, Scopus and Google Scholar. Scientometrics. 2008;74(2):257–271. doi: 10.1007/s11192-008-0216-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11192-008-0216-y</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>